PTEN is mutated in 6.41% of malignant solid tumor patients [3].

PTEN is an inclusion criterion in 36 clinical trials for malignant solid tumor, of which 29 are open and 7 are closed. Of the trials that contain PTEN status and malignant solid tumor as inclusion criteria, 15 are phase 1 (10 open), 7 are phase 1/phase 2 (5 open), 13 are phase 2 (13 open), and 1 is phase 4 (1 open) [4].

PTEN is mutated in 5.84% of breast carcinoma patients [3].

PTEN is an inclusion criterion in 29 clinical trials for breast carcinoma, of which 27 are open and 2 are closed. Of the trials that contain PTEN status and breast carcinoma as inclusion criteria, 8 are phase 1 (7 open), 5 are phase 1/phase 2 (4 open), 13 are phase 2 (13 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

PTEN is mutated in 13.56% of prostate carcinoma patients [3].

PTEN is an inclusion criterion in 12 clinical trials for prostate carcinoma, of which 9 are open and 3 are closed. Of the trials that contain PTEN status and prostate carcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 2 are phase 3 (2 open) [4].

PTEN is mutated in 3.56% of ovarian carcinoma patients [3].

PTEN is an inclusion criterion in 11 clinical trials for ovarian carcinoma, of which 8 are open and 3 are closed. Of the trials that contain PTEN status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 3 (0 open) [4].

PTEN is mutated in 13.52% of prostate adenocarcinoma patients [3].

PTEN is an inclusion criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain PTEN status and prostate adenocarcinoma as inclusion criteria, 10 are phase 2 (9 open) [4].

PTEN is mutated in 2.99% of non-small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 5 are open and 5 are closed. Of the trials that contain PTEN status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 4 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

PTEN is mutated in 40.38% of endometrial carcinoma patients [3].

PTEN is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

PTEN is mutated in 5.39% of colorectal carcinoma patients [3].

PTEN is an inclusion criterion in 6 clinical trials for colorectal carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [4].

PTEN is an inclusion criterion in 6 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 3 are closed. Of the trials that contain PTEN status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [4].

PTEN is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain PTEN status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

PTEN is mutated in 8.76% of squamous cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PTEN status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

PTEN is mutated in 6.86% of melanoma patients [3].

PTEN is an inclusion criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain PTEN status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 5 clinical trials for fallopian tube carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PTEN status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

PTEN is an inclusion criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

PTEN is mutated in 30.42% of glioblastoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for glioblastoma, of which 2 are open and 2 are closed. Of the trials that contain PTEN status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

PTEN is mutated in 8.54% of small cell lung carcinoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PTEN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

PTEN is mutated in 2.89% of non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

PTEN is mutated in 0.93% of pancreatic adenocarcinoma patients [3].

PTEN is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain PTEN status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

PTEN is mutated in 6.28% of cancer patients [3].

PTEN is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain PTEN status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (1 open) [4].

PTEN is mutated in 3.41% of gastric adenocarcinoma patients [3].

PTEN is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PTEN status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [4].

PTEN is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

PTEN is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 4 (1 open) [4].

PTEN is mutated in 24.17% of malignant glioma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

PTEN is mutated in 8.9% of oropharyngeal squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for oropharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is mutated in 5.34% of clear cell renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is mutated in 7.28% of leiomyosarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and leiomyosarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is mutated in 3.38% of gastric carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 3.06% of urothelial carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is mutated in 4.68% of soft tissue sarcoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.66% of gastrointestinal stromal tumor patients [3].

PTEN is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is mutated in 1.9% of cholangiocarcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is mutated in 0.91% of pancreatic carcinoma patients [3].

PTEN is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

PTEN is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

PTEN is mutated in 22.05% of diffuse glioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is mutated in 8.5% of anaplastic astrocytoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is mutated in 6.68% of cervical carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 5.0% of renal cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 5.36% of colorectal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 5.38% of malignant intestinal neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 5.12% of malignant small intestinal neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 3.73% of thyroid gland carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 3.72% of oral cavity squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 3.38% of malignant gastric neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 3.91% of malignant ovarian epithelial tumor patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 4.55% of undifferentiated pleomorphic sarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.67% of malignant esophagogastric neoplasm patients [3].

PTEN is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 2.95% of B-cell non-hodgkin lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.78% of mesothelioma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.33% of biliary tract carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.37% of esophageal carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 1.9% of bile duct adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 2.22% of esophageal adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 2.35% of lymphoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.89% of hepatocellular carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is mutated in 2.59% of high grade ovarian serous adenocarcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and angiosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for bannayan syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bannayan syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for cowden syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cowden syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for extraskeletal osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and extraskeletal osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for large cell/anaplastic medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

PTEN is mutated in 7.94% of laryngeal squamous cell carcinoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and myxofibrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTEN status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for proteus syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and proteus syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PTEN is mutated in 3.33% of rhabdomyosarcoma patients [3].

PTEN is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PTEN is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and uveal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].